Partners HealthCare News

Artificial intelligence is poised to change the pharmaceutical and healthcare industries as it looks to streamline, speed-up and improve overall efficiency. It might still be early days but it’s a bandwagon that organisations are quickly jumping on board. According to a CB Insights report, about 86% of healthcare organisations, life science companies and med tech…

BOSTON–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune today announced that they have entered into a definitive agreement for Alexion to acquire Syntimmune, a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcRn). SYNT001 – a humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes –…

Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles. This significant achievement is a milestone in the treatment of acne and follows the company’s completion of its pivotal study, which clearly demonstrated clinical efficacy…

Boston, Mass. – August 7, 2018 – Akouos, a precision genetic medicine company developing gene therapies that restore and preserve hearing, today announced the Company has raised $50 million in Series A financing. Seed investors 5AM Ventures and New Enterprise Associates (NEA) co-led the round, and were joined by existing seed investor Partners Innovation Fund and new…

Translate Bio, Inc. (Nasdaq: TBIO) a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross…

Lyndra Inc., an emerging biopharmaceutical company, today announced the formation of a joint venture with Global Drug Commercialization Center (GDCC) to commercialize Lyndra’s groundbreaking medicines in China. The partners held a public ribbon-cutting ceremony for the new Lyndra (China) Pharmaceuticals Co., Ltd. headquarters in Chengdu, China. Lyndra is developing ultra-long-acting oral therapies that free patients…

Magenta Therapeutics, a biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced treatment of the first patient with an inherited metabolic disorder in a Phase 2 study of MGTA-456.

Denali Therapeutics, a an early-stage biotech developing novel therapies for neurodegenerative diseases, raised $250 million by offering 13.9 million shares at $18, within the range of $17 to $19. At pricing, the company commands a fully diluted market value of $1.7 billion.  

Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced the closing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions.  In addition, Spero Therapeutics, Inc. has granted the…

Two biotechs, Spero Therapeutics and Allena Therapeutics, are headed for the Nasdaq this morning at valuations they’d been aiming for. Their stock offerings are the latest sign of the health of the biotech IPO market, and the willingness of insiders to make sure these deals succeed. For more information, click here

Magenta Therapeutics, a biotechnology company developing therapeutics to improve and expand the use of curative hematopoietic stem cell transplantation for more patients, today announced that it has been named by FierceBiotech as one of the Fierce 15 biotechnology companies of 2017. This award designates Magenta Therapeutics as one of the most promising private biotechnology companies…

Call for Submissions! Philips Wearables Challenge  The Philips Wearables Challenge is a call for novel solutions to predict early signs of patient deterioration in order to prevent hospital readmission and escalation in care throughout the patient journey. What cutting edge technologies and systems — wireless wearable sensors, connected devices, continuous, real-time monitoring, data analytics, etc. — can…

On May 17, Partners HealthCare joined forces with another Boston institution, GE Electric Co., to launch an ambitious 10-year collaboration to rapidly develop, validate, and strategically integrate deep learning technology into every aspect of the patient journey. Working with GE Healthcare, this decade-long effort will be executed through the newly formed Massachusetts General Hospital and…

Hospital owner eyes cutting-edge therapies Partners parceling out $1 million in grants by Lindsay Kalter, Boston Herald Saturday, October 22, 2016   Boston-based medical giant Partners HealthCare is doling out $1 million in grants to get cutting-edge therapies from food allergy cures to scarless biopsies on the market within five to seven years, and at least three…